Dr. Yakun Wan has been committed to the research and development of nanobody based drugs for over 17 years. He is the founder and CEO of Shanghai Novamab biopharmaceuticals. He has led the team to develop the world's first inhaled nanobody drugs LQ036 and LQ043H, which target IL-4R and TSLP. These two clinical projects will cover all patients with moderate to severe asthma. They are administered locally through inhalation and have fast onset of effect and low toxicity. Now, inhaled IL-4R and TSLP has completed clinical phase I studies respectively, which showed great safety and tolerability. In addition, Nomamab is developing innovative Nanbody based drug to treat IPF, cystic fibrosis and other immunology diseaes.